Osteoarthritis pain management with Meloxicam is now available by prescription at pharmacies across the United States.
Meloxicam capsules, a nonsteroidal anti-inflammatory drug is now available at pharmacies by prescription across the United States.
In 12-week study, patients with osteoarthritis pain received Meloxicam at low 5-mg and 10-mg doses and these capsules exhibited remarkable efficacy. Dose strengths of Meloxicam (5 and 10 mg) are 33% lower than oral Meloxicam products which are currently available. U.S. Food and Drug Administration approved Meloxicam for the pain management in patients with osteoarthritis.
Meloxicam now offers patients who are currently taking oral meloxicam an effective low-dose alternative that aligns with FDA prescribing recommendations to use the lowest effective dose of NSAIDs. The launch of Meloxicam further strengthens our commitment to provide effective low-dose NSAID options for patients experiencing pain."
Various serious adverse events of NSAID such as gastrointestinal ulcers, gastrointestinal bleeds, stroke, myocardial infarction and cardiovascular thrombotic events are reported by systematic reviews of observational studies. Such serious adverse events have evoked FDA and many professional medical organizations i.e The American College of Rheumatology, American Heart Association and American Gastroenterological Association and suggested to use NSAID at the lowest effective dose for the shortest possible duration.
Meloxicam X demonstrated significant pain relief at low 5 mg and 10 mg doses, and may present an important new treatment option for the 27 million Americans with osteoarthritis pain. This latest launch provides patients living with osteoarthritis pain an efficacious, yet low dose, NSAID that aligns with recommendations by the FDA and leading professional organizations to use the lowest effective dose.